Citations

Clear

572 citation(s) found for "Silva, P".

Differences in cognitive performance and neuroanatomy according to Alzheimer's disease pathophysiology
Ribeiro, Isadora Cristina , Gonçalves, Brenda Costa , Aventurato, Ítalo Karmann , Silva, Marjorie Cristina Rocha da , Rizzi, Liara , Rochetti, Ana Luiza Gonçalves , Fernandes, Gustavo Bruniera Peres , Cendes, Fernando, Balthazar, Marcio Luiz Figueredo , Cendes, Fernando , Cendes, Fernando

Mayo Clinic

Arquivos de Neuro-Psiquiatria | March 12, 2026 | Volume: 84 | Issue: 03 | Pages: 001-009

10.1055/s-0046-1817040 | PMID 41813037 Get It

Abstract The diagnosis of predementia stages indicates an increased risk of progression to dementia. The Amyloid, Tau, and Neurodegeneration AT(N) classification considers measurements of altered proteins and the presence of neurodegeneration to classify the risk groups regarding the pathophysiology of Alzheimer's disease (AD). The cognitive and anatomical characteristics of the patients in the predementia stage according to the AT(N) classification are not fully understood. To investigate whether there are differences in the clinical and anatomical profiles among older adults in the predementia stage according to the ATN classification, and to investigate the associations involving cognition and cortical thickness and subcortical volume in the AT(N) groups. In total, 72 older adults with subjective cognitive decline and mild cognitive impairment were allocated to groups according to the AT(N) classification (AD continuum: n = 37; suspected non-AD pathophysiology: n = 8; normal biomarkers: n = 27). The participants were investigated through cognitive tests, magnetic resonance imaging scans, and cerebrospinal fluid analyses. We used multivariate and univariate analyses with post-hoc testing to verify differences among groups. In addition, linear regressions were performed to verify the interactions involving cognition and gray matter metrics. The suspected non-AD pathophysiology group showed worse performance in attention/executive function than the AD continuum and normal biomarkers groups (p = 0.04). However, the ATN classification groups did not differ in terms of cortical thickness (p > 0.05). In addition, in the AD continuum group, memory was associated with left fusiform gyrus thickness (p = 0.000 uncorrected; r = 0.238). Cognition, but not gray matter metrics, differs among AT(N) classification groups. Memory is associated with cortical thickness in patients with positive amyloid Beta (AD continuum).
Very High vs. High Tumor Mutational Burden Across Tumors: Real-World Associations with MSI, Pathway Features, and Immunotherapy Outcomes
Teixeira, Maria Fernanda , Tomaz, Victoria, Silva, Lucas Campos Barbosa e, Donizete, Uelson, Tustumi, Francisco , Nakaya, Helder Imoto , Moura, Fernando, Borad, Mitesh, Junior, P. Serrano Uson, Usón, Pedro Luiz Serrano , Nakaya, Helder I. , Uson, Pedro L S , Tomaz, Victoria, Beal, Juliana Rodrigues , Moura, Fernando , Borad, Mitesh J. , Campregher, Paulo Vidal

Mayo Clinic

Biomedicines | March 6, 2026 | Volume: 14 | Issue: 3 | Pages: 593

10.3390/biomedicines14030593 | PMID 41898240 Get It

Background: Tumor mutational burden (TMB) is an FDA-approved biomarker for immune checkpoint inhibitor (ICI) therapy. However, its predictive value varies among tumor types and molecular contexts. We investigated whether a very high TMB identifies a biologically distinct subset and whether a higher cutoff provides additional clinical insights beyond the conventional high TMB threshold. Methods: We analyzed 133 patients with advanced solid tumors and TMB ≥ 10 mutations/Mb (mut/Mb) who underwent tumor genomic profiling using a 523-gene DNA/RNA next-generation sequencing panel. Tumors were stratified into prespecified TMB categories: 10–20 mut/Mb (TMB-H) and >20 mut/Mb (TMB-VH). The clinical characteristics, ICI outcomes (in the treated subset), and pathway-level genomic features were compared between groups. Results: TMB-VH was observed in 42/133 (31.6%) patients and spanned more than 20 tumor types. MSI was markedly more prevalent in TMB-VH than in TMB-H tumors (38.1% vs. 2.2%; Fisher’s exact p = 8.9 × 10−8). Pathway-level comparisons did not identify statistically significant differences after false discovery rate correction (all q > 0.05), and the observed patterns were descriptive in nature. In the ICI-treated subset with complete follow-up, objective response did not differ according to the TMB group. Overall survival (OS) was also similar between groups, whether measured from metastatic diagnosis (log-rank p = 0.937) or from ICI initiation (log-rank p = 0.814), although OS was numerically longer in the TMB-VH group in both analyses without reaching statistical significance. Conclusions: In this cohort study, TMB-VH was strongly associated with MSI but not independently associated with improved ICI outcomes. Larger multicenter cohorts are needed to validate pathway-oriented patterns and clarify the clinical utility of extreme TMB thresholds across various histologies. Integrating the functional context (e.g., MSI status, gene-level context, and pathway-level features) with TMB magnitude may enable more robust, tumor-aware biomarker models for immunotherapy selection.
Review 1: "Transient JAK/STAT Inhibition by Ruxolitinib Modulates Malaria-specific CD4+ T Cell Responses and Enhances Recall Immunity in Volunteers Experimentally Infected with Plasmodium Falciparum"
Silva, Henrique Borges da

Mayo Clinic

No container title available | February 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1162/2e3983f5.c5920a42 Get It

Disruption of CSF-1 receptor–mediated metal ion homeostasis in the murine brain promotes neurodegenerative disease
Chiţu, Violeta , Alvarenga, Julia, Chen, Wenna, Reynolds, David, Liu, Yang , Sun, Daqian, Sandell, A. , Karrenbauer, Virginjia Danylaite, Uvdal, P. , Silva, Iran An Da, Johansson, Ulf, Vignesh, Kavitha Subramanian , Wszolek, Zbigniew K., Dickson, Dennis W., Aguilan, Jennifer T. , Sidoli, Simone, Zheng, Deyou , Stanley, E. Richard, Karrenbauer, Virginija Danylaité , Danylaité Karrenbauer, Virginija , Sandt, Christophe , Klementieva, Oxana l. , Johansson, Ulf, Dickson, Dennis W. , Stanley, E. Richard

Mayo Clinic

Journal of Clinical Investigation | February 26, 2026 | Volume: 136 | Issue: 9 | Pages: No page available

10.1172/jci200121 | PMID 41746753 Get It

Dominant-inactivating mutations in the colony stimulating factor-1 receptor ( CSF1R ) cause CSF-1R–related leukoencephalopathy (CRL), an adult-onset neurodegenerative disease that is modeled in the Csf1r +/– mouse. CRL is caused by microglial dysfunction. However, the primary microglial deficit is unknown. To address this question, we employed single-nucleus RNA sequencing of brains from young Csf1r +/– mice without pathological or behavioral alterations. Reduction of CSF-1R signaling caused metal ion accumulation in brain macrophages, with concomitant activation of cell death and stress response pathways in oligodendrocytes and neuronal subpopulations. Reduction of metallothionein 1 ( Mt1 ) and 3 ( Mt3 ) gene expression was a common feature in glial and neuronal cells of Csf1r +/– mice. Overexpression of Mt1 restored metal ion homeostasis, normalized ROS production in microglia, and prevented the development of behavioral deficits, while Mt3 deletion had disease-enhancing effects. These findings demonstrate CSF-1R regulation of metal ion homeostasis via metallothioneins in the brain.
Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis
Tan, Carlyn Rose, Usmani, Saad Z., Derkach, Andriy , Corraes, Andre De Menezes Silva, Parrondo, Ricardo , Ailawadhi, S., Asoori, Sireesha, Dave, Mrugakshi, Popat, Rakesh, Morjaria, Oliver, Hajek, Roman , Htut, Myo , Kastritis, Efstathios, Dimopoulos, M A, Martínez-López, Joaquín, Nagarajan, Chandramouli, Bal, Susan, Costa, Luciano J., Einsele, Hermann, Steinbrunn, Torsten, Riedhammer, Christine , Banerjee, Rahul, Chng, Wee Joo, Tso, Allison CY, Lin, Yi, Martin, Tom, Mian, Hira, Martínez‐López, Joaquín , Mian, Hira , Tan, Carlyn R , de Meneze Silva Corraes, Andre, Mihalyova, Jana , Visram, Alissa , Kastritis, Efstathios , Martinez-Lopez, Joaquin , Nagarajan, Chandramouli , Bal, Susan , Costa, Luciano J , Waldschmidt, Johannes M , Banerjee, Rahul , Tso, Allison , Martin, Thomas , Mian, Hira , Parrondo, Ricardo D , Derkach, Andriy , Usmani, Saad Z. , Corraes, Andre De Menezes Silva , Ailawadhi, Sikander , Popat, Rakesh , Hájek, Roman , Janakiram, Murali , Visram, Alissa , Kastritis, Efstathios , Dimopoulos, Meletios Α. , Nagarajan, Chandramouli , Bal, Susan , Costa, Luciano J. , Steinbrunn, Torsten , Banerjee, Rahul , Chng, Wee Joo

Mayo Clinic

Blood Advances | February 24, 2026 | Volume: 10 | Issue: 9 | Pages: 2937-2946

10.1182/bloodadvances.2025019231 | PMID 41734378 Get It

Abstract Recent therapeutic advances, including bispecific antibodies (bsAbs), have improved outcomes for patients with relapsed/refractory multiple myeloma (RRMM). However, early mortality (EM) remains a significant challenge, even in the era of novel immunotherapies. We conducted a multicenter, retrospective analysis of real-world patients with RRMM treated with commercial bsAbs to evaluate the incidence and causes of EM. Between May 2022 and June 2025, a total of 441 patients were treated across 7 countries. EM, defined as death within 12 months of therapy initiation, occurred in 148 patients (34%), with a median time from bsAb initiation to death of 2.87 months (interquartile range, 1.38-6.85). The leading cause of EM was progressive disease (72%), followed by infection (13%); regardless of the cause of death, 82% had active disease at the time of death. Our findings highlight that despite encouraging efficacy, EM remains high among real-world bsAb recipients, emphasizing the need for improved disease control strategies and supportive care interventions.
Hypothalamic asymmetry in hemisphere-specific neuroendocrine signaling
Watanabe, Hiroyuki , Kobikov, Yaromir, Nosova, Olga , Lukoyanova, Alisa, Lindström, Emma , Ueta, Yoichi, Maruyama, Takashi, Ferreira, Rui Francisco, Silva, Susana Maria, Lukoyanov, Nikolay, Zhang, Mengliang, Sarkisyan, Daniil , Galatenko, Vladimir Vladimirovich , Ueta, Yoichi , Maruyama, Takashi, Grönbladh, Alfhild , Hallberg, Mathias , Schouenborg, Jens , Lukoyanov, Nikolay , Lavrov, Igor , Zhang, Mengliang , Bakalkin, Georgy

Mayo Clinic

No container title available | February 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.16.705997 Get It

ABSTRACT Brain lesions classically cause contralateral sensorimotor and postural deficits, attributed to the decussation of descending neural pathways. However, recent findings reveal that, beyond neural mechanisms, contralateral effects can also be mediated by the neuroendocrine system via humoral pathways. This raises the possibility that the brain regulates left- and right-sided peripheral processes through hypothalamic neurohormones released into the bloodstream. For such spatially targeted endocrine signaling to occur, hemisphere-specific neural activity must be encoded into side-specific hormonal output—requiring a lateralized organization of hypothalamic neuroendocrine systems. Here, we report molecular asymmetries in the rat hypothalamus that support this mechanism. Transcriptomic analysis revealed asymmetric expression of eleven neurohormonal genes, including Gnrh1 , Cck , and Trh , along with distinct left-right side-specific gene co-expression networks. Chemogenetic stimulation of Arg-vasopressin neurons in vasopressin-hM3Dq-mCherry transgenic rats produced generalized changes in these networks—predominantly in the right hypothalamus—suggesting that hypothalamic neurohormonal circuits function as integrated, lateralized ensembles. Stereological analysis revealed asymmetric coordination of vasopressin neurons within the paraventricular nucleus, with the left rostral region decoupled from the right rostral and caudal subregions. Functionally, gonadotropin-releasing hormone, cholecystokinin-8, and thyrotropin-releasing hormone—administered intracisternally in rats with complete spinal cord transection—elicited side-specific peripheral responses, measured as hindlimb postural asymmetry in a binary left–right output model. These neurohormonal effects were therefore transmitted via the humoral route. These findings suggest that multiple hypothalamic neurohormones and their integrated networks are asymmetrically organized, and that their lateralization may be necessary for hemisphere-specific hormonal regulation of peripheral systems.
Effectiveness of an Educational Intervention With Home Visits and Telephone Follow‐Up on Knowledge and Quality of Life in Patients With Heart Failure: A Randomized Clinical Trial
Marques, Cleidinaldo Ribeiro de Góes , Santos, Eduesley Santana , Silva, Luciane Souza da , Guimarães, Eryck Araujo de Castro, Santos, Tarcisio Gois dos, Sales, Vinícius Barbosa dos Santos , Silva, Wanessa Alves , Sousa, Antônio Carlos Sobral , de Goes Marques, Cleidinaldo Ribeiro , Dos Santos, Tarcisio Gois, Dos Santos Sales, Vinícius Barbosa , Guimarães, Eryck Araujo, Sousa, Antônio Carlos Sobral

Mayo Clinic

Nursing & Health Sciences | February 17, 2026 | Volume: 28 | Issue: 1 | Pages: No page available

10.1111/nhs.70309 | PMID 41699990 Get It

ABSTRACT Cardiovascular diseases, particularly heart failure (HF), are leading causes of morbidity and mortality worldwide. Limited patient knowledge about HF is associated with poor treatment adherence and worse health outcomes, emphasizing the importance of educational interventions. This randomized clinical trial evaluated the effectiveness of a nurse‐led educational intervention combining home visits and telephone follow‐up on patients' knowledge and quality of life (QoL). Conducted in six Brazilian hospitals, the study included 120 patients hospitalized with decompensated HF and randomly assigned to a control group (CG) or an intervention group (IG). The IG received structured education at discharge, followed by home visits on days 7, 30, and 60 and telephone follow‐up on days 15 and 45, while the CG received usual care. Outcomes were assessed at 60 days. At this time point, adequate HF knowledge was observed in 82% of patients in the IG compared with 38% in the CG, and good QoL in 73% versus 33%, respectively ( p < 0.001). The intervention was effective in improving knowledge and QoL in patients with HF.
Abstract GS1-01: Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer
Hamilton, E., Curigliano, G., Martín, M., Lerebours, F., Tsurutani, J., Savard, M., Jerzak, K. J., Hu, X., Pimentel, L. Martins de Aquino, O'Sullivan, CC, Tokunaga, Eriko , Huang, C., Jacot, W., Sohn, J., Silva, E. Cronemberger, Müller, Volkmar , Yang, S., Granata, G. , Shen, Qi , Santarpia, L., Diéras, V., Curigliano, Giuseppe , Tsurutani, Junji , Savard, M-F., Jerzak, Katarzyna J. , O’Sullivan, Ciara C. , Okines, Alicia , Jacot, William , Sohn, Joohyuk , Shen, Q., Santarpia, Libero , Dièras, Véronique

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: GS1-01-GS1-01

10.1158/1557-3265.sabcs25-gs1-01 Get It

Abstract Background: The current standard of care for first-line (1L) treatment of human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) consists of induction chemotherapy combined with trastuzumab (TRAS) and pertuzumab (PERT) followed by maintenance therapy with TRAS + PERT. Although this regimen has been associated with sustained disease control, most patients eventually experience disease progression. The HER2CLIMB-05(NCT05132582) study is investigating the efficacy and safety of adding tucatinib to TRAS + PERT as maintenance therapy in patients with HER2+ MBC after completion of 1L chemotherapy-based induction therapy. Methods: Patients with centrally confirmed HER2+MBC without evidence of progression after 1L induction therapy with 4 to 8cycles of a taxane combined with TRAS + PERT, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, and no or asymptomatic brain metastases (BM) were enrolled in HER2CLIMB-05. Contrast-enhanced brain magnetic resonance imaging was performed at screening and regular intervals during the study. Patients were randomly assigned 1:1 to receive either tucatinib 300 mg or placebo twice daily, in combination with either TRAS (6 mg/kg IV or 600 mg SC) plus PERT (420 mg/kg IV) or a SC fixed-dose combination of TRAS, PERT, and hyaluronidase administered every 21 days. Endocrine therapy was permitted for patients with hormone receptor-positive tumors. The primary endpoint is investigator-assessed progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints include overall survival (OS), PFS by blinded independent central review, investigator-assessed central nervous system (CNS)-PFS, and safety. Results: Between March 2022 and July 2024, 654 patients were randomly assigned to receive tucatinib (n = 326) or placebo (n = 328) with1L maintenance therapy. All patients were female (median age: 54 years [range, 24-83]);45.0% were White, 35.2% were Asian, 2.9% were Black/African American, and 19.3%were Hispanic/Latino(a)/Spanish origin. Most patients had ECOG PS of 0 (64.1%)and de novo metastatic disease (69.3%). At baseline, 12.4% of patients had presence or history of BM and 52.6% had hormone receptor-positive MBC. As of September5, 2025, PFS was statistically significantly improved with the addition of tucatinib versus placebo to 1L maintenance therapy (hazard ratio [HR] = 0.641 [95%confidence interval (CI), 0.514-0.799]; 2-sided P &lt; 0.0001). All prespecified patient subgroups demonstrated a PFS benefit with tucatinib combination 1L maintenance therapy consistent with the overall population and regardless of presence or absence of BM at baseline or hormone-receptor status. OS is still immature (observed number of deaths = 51;tucatinib arm versus control arm HR = 0.539 [95% CI, 0.303-0.957; 2-sided P= 0.032]). In the safety analysis set, the most common treatment-emergent adverse events (TEAEs) in the tucatinib arm (n = 326) were diarrhea (72.7%), nausea (33.1%), and elevated liver enzymes (alanine aminotransferase: 28.2%; aspartate aminotransferase:25.8%), of which 6.1%, 0.9%, 13.5%, and 7.1% were, respectively, grade ≥ 3. In the tucatinib arm, 13.5% of patients discontinued tucatinib due to TEAEs. Conclusions: In the HER2CLIMB-05 trial, the addition of tucatinib to TRAS + PERT as 1L maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in PFS with a manageable safety profile in patients with HER2+ MBC. Citation Format: E. Hamilton, G. Curigliano, M. Martin, F. Lerebours, J. Tsurutani, M. Savard, K. Jerzak, X. Hu, L. Martins de Aquino Pimentel, C. O'Sullivan, E. Tokunaga, A. Okines, C. Huang, W. Jacot, J. Sohn, E. Cronemberger Silva, V. Mueller, S. Yang, G. Granata, Q. Shen, L. Santarpia, V. Dieras Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr GS1-01.